Cooley advised Unchained Labs on its acquisition of Belgium-based life sciences company Trinean and its concurrent Series C financing round.
Trinean’s DropSense systems measure protein, DNA and RNA concentration in biologics and genomics samples. The system can measure up to 96 high concentration protein samples in 5 minutes.
Based in Pleasanton, California, Unchained Labs helps biologics researchers break free from tools that just don’t cut it.
The acquisition of Trinean marks the fifth acquisition on which Cooley has advised Unchained Labs since helping form the company in 2014.
Unchained Labs Inc. is a life sciences tools company. The company, led by Timothy A. Harkness, Wilhelm Lachnit, Krista Witte, Scott Lockard and Rick Gordon, offers Optim, a multiplex protein stability platform for biologics that lets researchers to measure multiple protein stability parameters, including denaturing temperature and aggregation onset temperature on multiple samples simultaneously; and GRUNT, an automated preparation system for biologic formulation.
Cooley partner Mark Weeks (Picture) led the team advising Unchained Labs.
Involved fees earner: Mark Weeks – Cooley LLP; Josh DuClos – Cooley LLP; Rishab Kumar – Cooley LLP; Jessica Girone – Cooley LLP; Nicole Orders – Cooley LLP; Allison Peth – Cooley LLP; Joshua Mates – Cooley LLP; Renee Deming – Cooley LLP; Erik Milch – Cooley LLP; Thomas Connors – Cooley LLP;
Law Firms: Cooley LLP;
Clients: Unchained Labs Inc.;